Zydus gets USFDA nod to Pimavanserin for Parkinson's disease-linked psychosis
Ahmedabad: Drugmaker, Zydus Cadila has received tentative approval from the US Food and drug Administration (USFDA) to market Pimavanserin Tablets, 10 mg (US RLD: Nuplazid Tablets).
Pimavanserin is used to treat the symptoms of a certain mental/mood disorder (psychosis) that might occur with Parkinson's disease. It helps lessen symptoms such as seeing or hearing things that are not there (hallucinations) and false beliefs (delusions).
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
The group now has 325 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Read also: Zydus Cadila novel compound to treat malaria ZY-19489 gets Orphan Drug Designation from USFDA
Zydus Cadila is a global pharmaceutical company headquartered in Ahmedabad, India.
The company discovers, develops, manufactures, and markets a broad range of healthcare therapies.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd